Annual Reports in Medicinal Chemistry: Roadmaps
- 1st Edition, Volume 62 - October 30, 2024
- Imprint: Academic Press
- Editor: Katherine Seley-Radtke
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 6 1 0 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 6 1 1 - 6
Annual Reports in Medicinal Chemistry: Roadmaps, Volume 62 highlights new advances in the field, with this new volume presenting interesting chapters written by an internati… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAnnual Reports in Medicinal Chemistry: Roadmaps, Volume 62 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors. This release provides a compendium of information on newly approved drugs and compounds entering late-stage clinical trials, making it a valuable resource for graduate students pursuing research in medicinal chemistry
- Reviews on hot topics of interest in small molecule drug discovery heavily pursued by industrial research organizations
- Provides preclinical information in the context of chemical structures
- Includes section editors who are highly knowledgeable and who can evaluate invited reviews for scientific rigor
Ideally suited for chemists engaged in multidisciplinary teams for drug discovery including medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry
1. Roadmap chapter on Antiparasitic natural products
Fyaz Ismail
2. Roadmap chapter on The hybrid antimalarial approach
Kamaljit Singh
3. Roadmap chapter on Antidiabetic natural products
Pulok K. Mukherjee
Fyaz Ismail
2. Roadmap chapter on The hybrid antimalarial approach
Kamaljit Singh
3. Roadmap chapter on Antidiabetic natural products
Pulok K. Mukherjee
- Edition: 1
- Volume: 62
- Published: October 30, 2024
- No. of pages (Hardback): 328
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443296109
- eBook ISBN: 9780443296116
KS
Katherine Seley-Radtke
Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to
nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic
emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently
used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as
the Program Director for UMBC’s Chemistry-Biology Interface graduate training program
funded by NIH since 2007. This program promotes hands on cross disciplinary research for
almost 50 PhD students from four departments at UMBC and UMB. She is currently the
Immediate Past President and Secretary-Elect for the International Society of Nucleosides,
Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral
Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections
and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,
Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Affiliations and expertise
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USARead Annual Reports in Medicinal Chemistry: Roadmaps on ScienceDirect